Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $152000.0.

  • X4 Pharmaceuticals' Gains from Investment Securities fell 3183.86% to $152000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $91000.0, marking a year-over-year decrease of 9382.63%. This contributed to the annual value of $639000.0 for FY2024, which is 18149.78% up from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Gains from Investment Securities is $152000.0, which was down 3183.86% from -$369000.0 recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Gains from Investment Securities high stood at $29.9 million for Q2 2023, and its period low was -$25.2 million during Q3 2023.
  • Its 5-year average for Gains from Investment Securities is $133000.0, with a median of $158000.0 in 2024.
  • Over the last 5 years, X4 Pharmaceuticals' Gains from Investment Securities had its largest YoY gain of 1706091.95% in 2023, and its largest YoY loss of 463250.0% in 2023.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Gains from Investment Securities stood at $1.3 million in 2021, then tumbled by 83.77% to $218000.0 in 2022, then soared by 344.95% to $970000.0 in 2023, then plummeted by 86.08% to $135000.0 in 2024, then increased by 12.59% to $152000.0 in 2025.
  • Its Gains from Investment Securities stands at $152000.0 for Q3 2025, versus -$369000.0 for Q2 2025 and $173000.0 for Q1 2025.